948557-43-5

948557-43-5 structure

Name: Tie2 kinase inhibitor
Chemical Name: 4-[4-(6-methoxynaphthalen-2-yl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine
CAS Number: 948557-43-5
Molecular Formula: C₂₆H₂₁N₃O₂S
Molecular Weight: 439.529
Catalog: Biochemical Inhibitor Protein tyrosine kinase
Create Date: 2018-11-29 06:58:51
Modify Date: 2025-08-27 10:49:56
Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM[1]. Tie2 kinase inhibitor 1 has anti-cancer activity[2].

Name	4-[4-(6-methoxynaphthalen-2-yl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine
Synonyms	S1577_Selleck X7496 4-{4-(6-Methoxy-2-naphthyl)-2-[4-(methylsulfinyl)phenyl]-1H-imidazol-5-yl}pyridine Tie2 kinase inhibitor-Supplied by Selleck Chemicals 4-{4-(6-methoxynaphthalen-2-yl)-2-[4-(methylsulfinyl)phenyl]-1H-imidazol-5-yl}pyridine Pyridine, 4-[4-(6-methoxy-2-naphthalenyl)-2-[4-(methylsulfinyl)phenyl]-1H-imidazol-5-yl]- Tie2 kinase inhibitor

Description	Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM[1]. Tie2 kinase inhibitor 1 has anti-cancer activity[2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
Target	IC50: 250 nM (Tie2)[1]
In Vitro	Tie2 kinase inhibitor 1 (compound 5) has an IC50 of 50 μM for p38 and has moderate to excellent cellular activities (cell IC50=232 nM)[1]. Tie2 kinase inhibitor 1 inhibits tunica internal endothelial cell kinase 2 (Tie2)[2].
In Vivo	Tie2 kinase inhibitor 1 (intraperitoneally; 50 mg/kg; twice a week for 6 weeks) results in statistically significant reductions in tumor volume by day 15. Tie2 kinase inhibitor 1 results in a 61% reduction in tumor volume by day 20, and reduces tumor volume by 45% by 6 weeks[1]. Animal Model: Athymic nude mice (6- to 8-week-old females)[1] Dosage: 50 mg/kg Administration: Intraperitoneally; twice a week for 6 weeks Result: Resulted in statistically significant reductions in tumor volume.
References	[1]. Semones M, et al. Pyridinylimidazole inhibitors of Tie2 kinase. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4756-60. Epub 2007 Jun 27. [2]. Hasenstein JR, et al. Efficacy of Tie2 receptor antagonism in angiosarcoma. Neoplasia. 2012 Feb;14(2):131-40.

Hazard Codes	N